tiprankstipranks
Trending News
More News >
Genfit SA (GNFT)
NASDAQ:GNFT
Advertisement

Genfit SA (GNFT) AI Stock Analysis

Compare
266 Followers

Top Page

GNFT

Genfit SA

(NASDAQ:GNFT)

Rating:61Neutral
Price Target:
$4.50
▲(8.70% Upside)
Genfit SA's overall stock score is driven by strong financial recovery and positive technical indicators. However, the high P/E ratio raises concerns about overvaluation. The absence of dividend yield and the need for improvements in operating efficiency and capital structure management are notable risks.
Positive Factors
Clinical Trials
Preliminary safety data from a study with GNS561 and trametinib in patients with KRAS-mutated cholangiocarcinoma supported the study's continuation, reflecting positive developments in their clinical trials.
Financial Stability
GENFIT entered into a royalty financing agreement with HealthCare Royalty (HCRx) for up to €185M in total funding, providing financial stability and resources for future projects.
Pipeline Development
Multiple clinical catalysts later in 2025 could boost confidence in the rare liver disease pipeline.
Research and Development
GENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on-Chronic Liver Failure (ACLF) programs, indicating progress in their research and development efforts.
Negative Factors
Debt Management
Plans to eliminate outstanding convertible debt should provide further capital flexibility for the company moving forward.
Patient Enrollment
A protocol amendment to improve the logistics of enrolling ACLF patients has been implemented to accelerate patient enrollment, indicating proactive steps to enhance clinical trial efficiency.

Genfit SA (GNFT) vs. SPDR S&P 500 ETF (SPY)

Genfit SA Business Overview & Revenue Model

Company DescriptionGenfit SA (GNFT) is a biopharmaceutical company focused on developing innovative therapeutic and diagnostic solutions for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and other liver-related conditions. The company operates primarily in the healthcare sector, emphasizing research and development to advance its portfolio of drug candidates and diagnostic tools aimed at improving patient outcomes in liver diseases and metabolic disorders.
How the Company Makes MoneyGenfit generates revenue through multiple streams, primarily from the development and commercialization of its pharmaceutical products. The company focuses on advancing its lead drug candidates through clinical trials, aiming for regulatory approvals that can lead to market entry. In addition to potential sales from its proprietary drugs, Genfit may also derive revenue from partnerships and collaborations with other pharmaceutical companies, which can include upfront payments, milestone payments, and royalties on future sales. Furthermore, Genfit has a diagnostic business segment, where it offers tests that assess liver health, contributing to its overall revenue. Strategic alliances with research institutions and industry partners enhance its capabilities and support its financial growth.

Genfit SA Financial Statement Overview

Summary
Genfit SA has shown a significant recovery in 2024, with a strong gross profit margin and improved cash flow generation. However, operating margins and leverage ratios indicate ongoing risks, necessitating strategic improvements in efficiency and capital structure management.
Income Statement
62
Positive
Genfit SA's income statement shows a significant recovery in 2024, with total revenue increasing by 134.5% from 2023. The gross profit margin is strong at 99.55% due to high gross profits relative to revenue. The company has turned around its net profitability with a net profit margin of 2.25% in 2024 compared to losses in previous years. However, the EBIT and EBITDA margins remain relatively low at 4.90% and 12.41%, indicating room for improvement in operating efficiency.
Balance Sheet
58
Neutral
Genfit SA's balance sheet reflects moderate stability with a debt-to-equity ratio of 0.90, suggesting a balanced use of debt and equity. The return on equity (ROE) is modest at 2.18%, reflecting limited profitability relative to equity. The equity ratio of 45.72% indicates a fair portion of assets are funded by equity, providing a stable foundation, yet there's a need to enhance asset efficiency and leverage.
Cash Flow
65
Positive
The cash flow statement shows a significant improvement in 2024 with a positive free cash flow of €14.57 million compared to a negative free cash flow in 2023. This indicates better cash generation from operations. The operating cash flow to net income ratio of 10.32 is strong, reflecting effective cash conversion from income. However, the past volatility in cash flows warrants careful monitoring.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue78.19M67.00M28.57M20.20M80.07M765.00K
Gross Profit77.32M66.70M28.22M19.95M79.91M563.00K
EBITDA24.65M8.32M-22.24M-23.60M34.91M-91.14M
Net Income22.27M1.51M-28.89M-23.72M67.26M-101.22M
Balance Sheet
Total Assets194.78M151.42M173.87M215.54M281.72M198.61M
Cash, Cash Equivalents and Short-Term Investments61.65M81.79M77.79M140.55M258.76M171.03M
Total Debt67.80M62.13M70.18M75.28M74.23M185.69M
Total Liabilities97.41M82.20M105.92M121.01M162.62M214.78M
Stockholders Equity97.36M69.22M67.95M94.53M119.10M-16.16M
Cash Flow
Free Cash Flow-42.69M14.57M-57.92M-72.64M99.38M-97.27M
Operating Cash Flow-41.54M15.55M-55.43M-72.64M99.92M-96.37M
Investing Cash Flow-1.14M-1.04M2.23M-46.27M-3.38M-966.00K
Financing Cash Flow-7.56M-10.57M-5.10M-3.79M-8.92M-8.26M

Genfit SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.14
Price Trends
50DMA
3.93
Positive
100DMA
3.96
Positive
200DMA
3.91
Positive
Market Momentum
MACD
0.09
Negative
RSI
52.26
Neutral
STOCH
33.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNFT, the sentiment is Positive. The current price of 4.14 is above the 20-day moving average (MA) of 4.03, above the 50-day MA of 3.93, and above the 200-day MA of 3.91, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 52.26 is Neutral, neither overbought nor oversold. The STOCH value of 33.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNFT.

Genfit SA Risk Analysis

Genfit SA disclosed 73 risk factors in its most recent earnings report. Genfit SA reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Genfit SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$204.69M123.872.17%134.52%
52
Neutral
$304.97M-38.87%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
44
Neutral
$388.04M-24.31%-1.34%11.93%
42
Neutral
$222.82M-33.97%
40
Underperform
$298.08M87.26%10.15%
39
Underperform
$186.63M-77.83%43.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GNFT
Genfit SA
4.14
-0.07
-1.66%
OMER
Omeros
4.25
0.21
5.20%
YMAB
Y-Mabs Therapeutics
8.55
-6.84
-44.44%
RAPT
RAPT Therapeutics
11.65
-6.51
-35.85%
FDMT
4D Molecular Therapeutics
6.46
-8.84
-57.78%
ENGN
enGene Holdings
4.34
-2.18
-33.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025